Merck & Co. (MRK)
(Delayed Data from NYSE)
$111.53 USD
+1.84 (1.68%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $111.47 -0.06 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.53 USD
+1.84 (1.68%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $111.47 -0.06 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Merck (MRK) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
The latest trading day saw Merck (MRK) settling at $111.53, representing a +1.68% change from its previous close.
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
by Zacks Equity Research
EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) concluded the recent trading session at $110.27, signifying a +1.61% move from its prior day's close.
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
by Zacks Equity Research
While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.
Stock Market News for Oct 4, 2024
by Zacks Equity Research
U.S. stock markets closed lower on Thursday after a choppy session.
Merck (MRK) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Merck (MRK) concluded the recent trading session at $110.18, signifying a -1.7% move from its prior day's close.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
by Kinjel Shah
JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $113.09, marking a -1.43% move from the previous day.
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
by Zacks Equity Research
The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal
by Zacks Equity Research
AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.
Company News for Sep 24, 2024
by Zacks Equity Research
Companies in The News Are: TSLA, DPZ, INTC, APO, MRK
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
by Zacks Equity Research
If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.
MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers
by Zacks Equity Research
The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers.
Merck (MRK) Stock Moves -0.05%: What You Should Know
by Zacks Equity Research
Merck (MRK) reachead $117.17 at the closing of the latest trading day, reflecting a -0.05% change compared to its last close.
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
by Kinjel Shah
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
Merck Loses Around $32B in 3 Months: Time to Sell the Stock?
by Kinjel Shah
Declining estimates and the recent price drop make investors skeptical about holding MRK stock.
Merck (MRK) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
by Zacks Equity Research
The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first approval for the given indication.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
by Zacks Equity Research
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
by Zacks Equity Research
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
by Zacks Equity Research
NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.